FDA Still Behind Tysabri Monotherapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Medwatch warning is less strident than some feared.
You may also be interested in...
Biogen Idec Reports First Tysabri PML Case In U.S.
Report is “not unexpected,” FDA says, but adverse event is not yet a non-event for Biogen and Elan.
Biogen Idec Reports First Tysabri PML Case In U.S.
Report is “not unexpected,” FDA says, but adverse event is not yet a non-event for Biogen and Elan.
Raptiva PML Case Brings Another REMS
FDA wants black-box warning, new safety plan for psoriasis drug.